Title | Tumor ablation using low-intensity ultrasound and sound excitable drug. |
Publication Type | Journal Article |
Year of Publication | 2017 |
Authors | Tung C-H, Han MShin, Kim Y, Qi J, O'Neill BE |
Journal | J Control Release |
Volume | 258 |
Pagination | 67-72 |
Date Published | 2017 07 28 |
ISSN | 1873-4995 |
Keywords | Animals, Antineoplastic Agents, Breast Neoplasms, Cell Line, Tumor, Combined Modality Therapy, Female, Humans, Mice, Mice, Inbred BALB C, Mice, Nude, Rose Bengal, Ultrasonic Therapy, Xanthenes |
Abstract | The cell membrane is a semi-fluid container that defines the boundary of cells, and provides an enclosed environment for vital biological processes. A sound excitable drug (SED) that is non-cytotoxic to cells is developed to disrupt the plasma membrane under gentle ultrasound insonation, 1MHz, 1W/cm. The frequency and power density of insonation are within the physical therapy and medical imaging windows; thus the applied ultrasound is safe and not harmful to tissues. The insertion of SEDs into the plasma membrane is not toxic to cells; however, the intruding SEDs weaken the membrane's integrity. Under insonation, the ultrasound energy destabilized the SED disrupted membranes, resulting in membrane rupture and eventual cell death. In a xenograft breast tumor model, the SED alone or the ultrasound alone caused little adverse effects to tumor tissue, while the combined treatment triggered necrosis with a brief local insonation of 3min. The described sono-membrane rupture therapy could be a safe alternative to the currently used high-energy tissue ablation technology, which uses X-rays, gamma rays, electron beams, protons, or high-intensity focused ultrasound. |
DOI | 10.1016/j.jconrel.2017.05.009 |
Alternate Journal | J Control Release |
PubMed ID | 28499816 |
PubMed Central ID | PMC5515481 |
Grant List | R01 GM094880 / GM / NIGMS NIH HHS / United States |
Related Institute:
Molecular Imaging Innovations Institute (MI3)